Key Highlights

  • Aurora Cannabis (NASDAQ:ACB) agreed on November 2, 2026 to be acquired by Organigram for an elective CAD 7.80 in cash per share, or 5.8626 Organigram shares, or a mix of the two.
  • The offer carries a 93% premium to the August 10, 2026 unaffected price and sits 21% above the implied value of Curaleaf's hostile bid, with Equity value near CAD 561 million fully diluted.
  • Proration caps limit the total to 205,826,172 Organigram shares and CAD 253,638,772 in cash, so each holder's final mix may differ from the election made.
  • Shareholder meetings are expected in December 2026, with closing targeted for January 2027 after court, TSX and regulatory approvals, including German clearance.

The Terms and the Competing Bid

The arrangement agreement was signed on November 2, 2026 and announced on November 3. Each Aurora Cannabis (NASDAQ:ACB) holder may elect CAD 7.80 in cash, 5.8626 Organigram shares, or CAD 3.75 in cash plus 3.0431 Organigram shares, all subject to proration. Both boards approved the deal unanimously, and Aurora's board rejected the hostile bid from Curaleaf. Coverage says Curaleaf has left its bid open since the Organigram agreement. The 93% premium is measured against the August 10, 2026 price, which predates the contest, so a share price above that level is what one would expect. Organigram's chief executive described the transaction as a defining step toward a disciplined, global cannabis leader.

Financing and Conditions

Organigram (NASDAQ:OGI) plans a private Placement with BAT of 141.0 million shares, described as 100 million pounds or about CAD 187.5 million, alongside an ATB Credit Facility of up to CAD 210 million. The per-share price for the placement is inconsistent across the release, so it is left out here. BAT holds about 30% of Organigram's votes and has signed an irrevocable voting agreement. Aurora needs two-thirds of the votes cast plus a majority of the minority under MI 61-101, while Organigram needs a simple majority excluding BAT. A British Columbia court, the TSX and regulators must also sign off. Fairness opinions came from BMO, Fort Capital and Origin Merchant Partners. Special meetings are expected in December 2026, and the arrangement is a court-approved plan under British Columbia corporate law.

Risks and What to Watch

The main risks are a higher or revised Curaleaf offer, proration that leaves holders with a different mix from the one they picked, a failed vote and the exposure of taking Organigram stock, whose value depends on the combined company. Published market data showed Aurora shares up about 22%. The break fee was not disclosed. Cannabis equities are volatile, and a handful of trades can move quotes sharply. Anyone holding Aurora Cannabis (NASDAQ:ACB) should read the circular, which will set out the election mechanics and meeting date. Curaleaf has not withdrawn, so a higher bid is still possible, though none has been announced. Holders who want certainty may prefer cash, while those seeking upside in the combined Business may elect shares.

Where Things Stand

Aurora Cannabis (NASDAQ:ACB) holders can only collect if the arrangement is approved, and a 93% premium to the unaffected price is a strong headline, yet the fight with Curaleaf is not over. The Organigram offer is 21% above the implied value of that rival bid, and it has board support and a major Shareholder behind it. Watch the December meetings, any revised Curaleaf proposal and the proration result before treating the premium as locked in. Cash elections are capped, so not every holder will receive all cash. Nothing here is Investment advice.